18.4.2012

Notwithstanding the impressive progress of the Company and its market positioning, the lack of approved treatments in the market and the numerous questions and concerns about the activity make pricing of Pluristem very difficult, similar to the other companies in the field. Accordingly, considering only the CLI indication, we have set a target price of $4.2 per share, with the recommendation of Buy.

Leader Capital Markets real estate analyst Ramon Amit wrote a paper suggesting that people worried about housing prices but wanting exposure to Israel's property market should do it through stocks